Overview

INVESTOR RELATIONS

May 6, 2026
Lunai Bioworks Completes $20 Million Preferred Issuance to Acquire CNS Delivery and Neurotherapeutic IP
https://lunaibioworks.com/news/news-details/

Overview

Latest News

View all news

Latest Presentation

View All Presentations

Quick Links

SEC Filings
Investor FAQs
Information Request Form

Investor Email Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At Renovaro BioSciences Inc., we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to Renovaro BioSciences Inc. to send you the requested Investor Email Alert updates.

* Required

Email Address *

Investor Alert Options

Investor Alert Options *

News
Quarterly Reports
Annual Reports
SEC Filings
End of Day Stock Quote
Events & Presentations

Unsubscribe

Email Alert Sign Up Confirmation

Privacy Policy
Site Map